Klonoff David C, Kerr David, Wong Jenise C, Pavlovic Yarmela, Koliwad Suneil, Hu Julia, Salber Patricia, Aguilera Adrian, Long William, Hamilton Giles, Chen Kong Y, Adi Saleh
1 Mills-Peninsula Medical Center, San Mateo, CA, USA.
2 William Sansum Diabetes Center, Santa Barbara, CA, USA.
J Diabetes Sci Technol. 2017 Sep;11(5):1045-1052. doi: 10.1177/1932296817723037. Epub 2017 Aug 8.
The purpose of developing mobile applications for diabetes is generally to: (1) provide enhanced access to timely information for patients, health care professionals, and researchers; (2) facilitate remote monitoring and diagnosis of patients, often based on information delivered by wearable devices; (3) provide decision support to assist patients in selecting treatment; or (4) deliver timely recommendations for treatment to increase adherence to prescribed therapy. There is a perception that mobile applications can provide meaningful clinical benefits, however, there is only sparse convincing evidence to support this belief at the present time. Compounding this problem is the short life span of digital software, such that if a traditional type of randomized controlled trial is conducted on a product, by the time the study has been designed, approved by an IRB, conducted, and analyzed, the product might have significantly changed to a next generation system. Because of great interest in establishing what are the potential benefits, metrics of success, and appropriate components of mobile applications for diabetes, Diabetes Technology Society and William Sansum Diabetes Center launched the Digital Diabetes Congress, March 7-8, 2017, in San Francisco. This report contains summaries of the meeting's 12 sessions. Each summary was written by the session's moderator who helped develop the session prior to the event and keep it on track during the event. This meeting report presents a summary of how 57 panelists, speakers, and moderators, who are leaders in digital health, see the current and future landscape of digital health tools applied to diabetes.
（1）为患者、医疗保健专业人员和研究人员提供更多获取及时信息的途径；（2）促进对患者的远程监测和诊断，通常基于可穿戴设备提供的信息；（3）提供决策支持，以协助患者选择治疗方案；或（4）提供及时的治疗建议，以提高对规定治疗的依从性。人们认为移动应用程序可以带来有意义的临床益处，然而，目前仅有少量有说服力的证据支持这一观点。使问题更加复杂的是数字软件的寿命较短，以至于如果对一种产品进行传统类型的随机对照试验，在研究设计、经机构审查委员会批准、实施和分析时，该产品可能已显著升级为下一代系统。由于人们对确定糖尿病移动应用程序的潜在益处、成功指标和适当组成部分非常感兴趣，糖尿病技术协会和威廉·桑萨姆糖尿病中心于2017年3月7日至8日在旧金山举办了数字糖尿病大会。本报告包含了该会议12场会议的总结。每份总结均由会议主持人撰写，主持人在会议前协助策划会议，并在会议期间确保其按计划进行。本会议报告概述了57位数字健康领域的专家、演讲者和主持人如何看待应用于糖尿病的数字健康工具的当前和未来前景。
